This grant supports academic and biotech researchers in developing new drugs to prevent, slow, or treat Alzheimer’s disease through preclinical and early-stage clinical research.
Funding for Alzheimer's drug development from pre-clinical to Phase I clinical trials to prevent, slow, or treat AD symptoms, excluding basic research and non-pharmacological interventions.
Drug Development RFP supports researchers and clinicians developing drugs and devices through IND-enabling studies and early clinical trials to advance treatments for Alzheimer’s disease and related dementias.
This grant supports combined Phase 1/2a clinical trials testing new drugs (excluding amyloid/tau targets) for Alzheimer's, using a milestone-driven approach.
Use mouse models to test existing and investigational drugs for Alzheimer's; focus on drug repositioning and combo therapy development.
NIH supports genome editing and other biologic therapies for Alzheimer's disease-related dementias, from lead optimization and drug development through safety studies and early clinical evaluation.